SEC Form 4 · accession 0001104659-17-043896
IMMUNOMEDICS INC · IMMU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Garone
Officer — Chief Financial Officer
Period of report
Jul 3, 2017
Accepted (ET)
Jul 6, 2017 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000722830
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | — | Jul 3, 2017 | A | 8,315 | A | — | — | Common Stock, par value $0.01 per share | 8,315 | 8,315 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Immunomedics, Inc. common stock. The restricted stock units shall vest as to one-third of the underlying shares on each of the first, second and third anniversaries of the date of grant. Vesting as to all of the underlying shares shall accelerate immediately upon certain termination events.